Trauma Clinical Trial
Official title:
Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge in Trauma and Obstetric Hemorrhage
NCT number | NCT03912545 |
Other study ID # | HEMCS-019 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 4, 2019 |
Est. completion date | July 11, 2019 |
Verified date | September 2019 |
Source | HemoSonics LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This pilot study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QStat Cartridge in trauma patients or patients with OB hemorrhage.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 11, 2019 |
Est. primary completion date | July 11, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subject is = 18 years of age - Subject has one of the following conditions and is a candidate for a ROTEM test to be performed to access coagulopathy: trauma patient; patient with OB hemorrhage. - For trauma patients; subject must be experiencing major trauma (preferably requiring the highest level of team activation) with active bleeding or deemed at high risk of significant bleeding according to mechanism of injury. - For subjects experiencing OB hemorrhage, one of the following conditions must be met (to be confirmed): - Estimated blood loss during vaginal delivery is greater than 1000 mL - Estimated blood loss during cesarean delivery is greater than 1500 mL - Placental abruption with hemorrhage of any quantity blood loss - Clinically suspected disseminated intravascular coagulation (DIC) - Is under consideration for administration of tranexamic acid (TXA) for treatment of hemorrhage. - Subject is willing to participate, and is willing to consent (either prospectively or by deferred consent) Exclusion Criteria: - Subject is younger than 18 years of age - Subject is known to have received antifibrinolytic therapy immediately prior to presentation to trauma unit or during labor just prior to OB hemorrhage. - Subject is unable to provide written informed consent (either prior to performing any study related procedures or by deferred consent) - Subject is currently enrolled in a distinct study that might confound the results of the proposed study - Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks. |
Country | Name | City | State |
---|---|---|---|
United States | Texas Tech University Health Sciences Center El Paso | El Paso | Texas |
Lead Sponsor | Collaborator |
---|---|
HemoSonics LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of Quantra Clot Time and Clot Stiffness results to standard coagulation test results | Coagulation function assessed by Quantra and standard coagulation tests | Upon arrival to emergency department (trauma subjects) or upon presentation with obstetric hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays | |
Primary | Comparison of Quantra Clot Time and Clot Stiffness results to ROTEM Delta results | Coagulation function assessed by Quantra and ROTEM Delta | Upon arrival to emergency department (trauma subjects) or upon presentation with OB hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays | |
Primary | Comparison of Quantra Fibrinolysis results to ROTEM Delta results | Coagulation function assessed by Quantra and ROTEM Delta | Upon arrival to emergency department (trauma subjects) or upon presentation with OB hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04848376 -
Post-Market Clinical Follow-up Study of A-SPINE's Products
|
||
Terminated |
NCT03781817 -
Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
|
Phase 4 | |
Completed |
NCT04342416 -
Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women
|
N/A | |
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Completed |
NCT05669313 -
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
|
||
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Recruiting |
NCT04725721 -
Testing FIRST in Youth Outpatient Psychotherapy
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT03696563 -
FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS
|
N/A | |
Withdrawn |
NCT03249129 -
Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
|
||
Completed |
NCT02240732 -
Surgical Tourniquets and Cerebral Emboli
|
N/A | |
Completed |
NCT02227979 -
Effects of PURPLE Cry Intervention
|
N/A | |
Withdrawn |
NCT01169025 -
Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients
|
N/A | |
Recruiting |
NCT01812941 -
Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients
|
N/A | |
Completed |
NCT03112304 -
Child STEPS for Youth Mental Health in Maine Sustainability
|
N/A | |
Completed |
NCT01475344 -
Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)
|
Phase 1/Phase 2 | |
Completed |
NCT01201863 -
Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
|
Phase 4 | |
Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A |